Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.The trial evaluated zanzalintinib plus Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) versus Bayer AG’s (OTC:BAYRY) Stivarga (regorafenib) for previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC).In June, the company said the study met one of its dual primary endpoints, demonstrating a 20% reduction in the risk of death ...